Log in to your account

Welcome back! Please enter your details.

Email

Password

Leave this field blank

Forgot password?

Don’t have an account? Create your account now!

Are you a healthcare professional?

This website is intended for healthcare professionals in the United Kingdom and Europe. Please confirm you are a healthcare professional before entering this website.

I am a healthcare professional I am not a healthcare professional

Consider creating a UCB account for full access or login to your existing account.

You are now leaving this website.

You are leaving the Rare Disease Connect in Neurology website and are about to enter the website of a third party. UCB is not responsible for the content of the website you are about to enter.

Cancel Continue

Image

This educational programme is organised and funded by UCB Biopharma SRL, and is intended for practising healthcare professionals interested in the area of myasthenia gravis (MG), thymidine kinase 2 deficiency (TK2d), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and managing patients in these spaces. Terms and conditions apply.

Image

This educational programme is organised and funded by UCB Biopharma SRL, and is intended for practising healthcare professionals interested in the area of myasthenia gravis (MG), thymidine kinase 2 deficiency (TK2d), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and managing patients in these spaces. Terms and conditions apply.

Image

This educational programme is organised and funded by UCB Biopharma SRL, and is intended for practising healthcare professionals interested in the area of myasthenia gravis (MG), thymidine kinase 2 deficiency (TK2d), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and managing patients in these spaces. Terms and conditions apply.

Image

This educational programme is organised and funded by UCB Biopharma SRL, and is intended for practising healthcare professionals interested in the area of myasthenia gravis (MG), thymidine kinase 2 deficiency (TK2d), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and managing patients in these spaces. Terms and conditions apply.

Sitemap

You are here:

Footer Bottom

Privacy Policy Terms and Conditions Cookie Policy Cookie Preferences Social Media Community Guidelines Contact us

Some images on this site are AI-generated using Microsoft Copilot. The site owner holds the rights to these images.
These images are for illustrative purposes only.

This website is not intended to be used for reporting adverse events related to UCB’s products. However, if you have any adverse events to report then please follow the current regulatory procedure in force in your country or click here to access the contact page of the UCB corporate website where you can report adverse events to us through local affiliate contacts, UCBCares or the completion of the UCB AE webform.

If you are a user from British or Irish Islands, reporting forms and information can be found at Yellow Card Reporting Site for the UK and Report an issue for Ireland. Adverse events should also be reported to UCB.

GL-DA-2300527 Date of preparation: January 2026

Image